Atovaquone
Atovaquone is a pharmaceutical drug with 16 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 13 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
5
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
13 of 13 finished
0.0%
0 ended early
2
trials recruiting
16
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)
Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides
Clinical Trials (16)
Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)
Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides
A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children
Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children
Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis
Atovaquone as Tumour HypOxia Modifier
Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension
A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients
A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole
A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia
An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine
A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX
A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine
All 16 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 16